Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics to treat life-threatening diseases. The company's pipeline includes several drug candidates for the treatment of pulmonary arterial hypertension, idiopathic pulmonary fibrosis, and other serious conditions. Gossamer Bio was founded in 2015 by former executives of Receptos, a biotech company that was acquired by Celgene for $7.2 billion. The company is headquartered in San Francisco, California, and has a research and development facility in San Diego, California. Gossamer Bio is committed to advancing innovative therapies that have the potential to improve the lives of patients around the world.